文献速递神经免疫

进展型多发性硬化症的肠道微生物组

Gut Microbiome in Progressive Multiple Sclerosis.
PubMed 文献 · Ann Neurol · 2021-04-30

该研究对健康对照、复发缓解型MS和进展型MS患者的肠道菌群进行测序,并与EDSS、生活质量和脑MRI病灶/萎缩等临床特征关联;同时用MS来源的Akkermansia定植小鼠并诱导EAE。结果显示MS患者与对照的菌群β多样性存在差异,进展型MS有独特菌群改变,且Akkermansia与较低残疾相关并减轻EAE。

要点

  • MS患者与健康对照的肠道菌群β多样性存在差异,但复发缓解型与进展型MS之间无差异。
  • 进展型MS独有肠杆菌科和Clostridium g24 FCEY升高、Blautia和Agathobaculum降低。
  • MS来源的Akkermansia可减轻EAE,与降低残疾相关,提示可能为有益补偿反应。

核心结论

  • 复发型和进展型MS存在部分共享的菌群改变,但进展型MS有独特细菌与疾病临床指标相关。
  • MS中Akkermansia升高可能与较低残疾相关,并可能为MS微生物组的补偿性有益反应。

研究设计与样本

  • 研究对健康对照、复发缓解型MS和进展型MS患者进行 microbiota 测序,并将细菌水平与EDSS、生活质量和脑MRI病灶/萎缩相关。
  • 研究用MS来源的Akkermansia定植小鼠并诱导实验性自身免疫性脑脊髓炎(EAE)。

主要发现

  • MS患者与对照的 microbiota β多样性存在差异,但复发缓解型与进展型MS之间无差异,也不随疾病修饰治疗而不同。
  • 疾病状态对微生物组β多样性影响最大,其次为体重指数、种族和性别。
  • 进展型MS和复发缓解型MS均可见Clostridium bolteae、Ruthenibacterium lactatiformans和Akkermansia增加,Blautia wexlerae、Dorea formicigenerans和Erysipelotrichaceae CCMM减少。
  • 进展型MS独有肠杆菌科和Clostridium g24 FCEY升高,Blautia和Agathobaculum降低。
  • 若干Clostridium species与较高EDSS和疲劳评分相关;Akkermansia与较低残疾相关,MS来源Akkermansia减轻EAE并减少RORγt+和产IL-17的γδ T细胞。

临床怎么用

  • 在进展型MS中可关注肠杆菌科升高及Blautia、Agathobaculum降低等独特菌群特征。
  • Akkermansia升高不应简单视为有害,其与较低残疾相关,可能具有有益作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study was undertaken to investigate the gut microbiome in progressive multiple sclerosis (MS) and how it relates to clinical disease. METHODS: We sequenced the microbiota from healthy controls and relapsing-remitting MS (RRMS) and progressive MS patients and correlated the levels of bacteria with clinical features of disease, including Expanded Disability Status Scale (EDSS), quality of life, and brain magnetic resonance imaging lesions/atrophy. We colonized mice with MS-derived Akkermansia and induced experimental autoimmune encephalomyelitis (EAE). RESULTS: Microbiota β-diversity differed between MS patients and controls but did not differ between RRMS and progressive MS or differ based on disease-modifying therapies. Disease status had the greatest effect on the microbiome β-diversity, followed by body mass index, race, and sex. In both progressive MS and RRMS, we found increased Clostridium bolteae, Ruthenibacterium lactatiformans, and Akkermansia and decreased Blautia wexlerae, Dorea formicigenerans, and Erysipelotrichaceae CCMM. Unique to progressive MS, we found elevated Enterobacteriaceae and Clostridium g24 FCEY and decreased Blautia and Agathobaculum. Several Clostridium species were associated with higher EDSS and fatigue scores. Contrary to the view that elevated Akkermansia in MS has a detrimental role, we found that Akkermansia was linked to lower disability, suggesting a beneficial role. Consistent with this, we found that Akkermansia isolated from MS patients ameliorated EAE, which was linked to a reduction in RORγt+ and IL-17-producing γδ T cells. INTERPRETATION: Whereas some microbiota alterations are shared in relapsing and progressive MS, we identified unique bacteria associated with progressive MS and clinical measures of disease. Furthermore, elevated Akkermansia in MS may be a compensatory beneficial response in the MS microbiome. ANN NEUROL 2021;89:1195-1211.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Cox LM, Maghzi AH, Liu S, et al. Gut Microbiome in Progressive Multiple Sclerosis. Ann Neurol. 2021. PMID: 33876477. doi:10.1002/ana.26084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。